Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) FCF Margin (2022 - 2025)

Atara Biotherapeutics' FCF Margin history spans 4 years, with the latest figure at 357.18% for Q4 2025.

  • For Q4 2025, FCF Margin fell 28219.0% year-over-year to 357.18%; the TTM value through Dec 2025 reached 42.18%, up 1131.0%, while the annual FY2025 figure was 42.18%, 1131.0% up from the prior year.
  • FCF Margin reached 357.18% in Q4 2025 per ATRA's latest filing, down from 283.43% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 9.93% in Q3 2024 to a low of 27619.0% in Q4 2022.
  • Average FCF Margin over 4 years is 2871.73%, with a median of 320.31% recorded in 2025.
  • The largest YoY upside for FCF Margin was 2641304bps in 2023 against a maximum downside of -652769bps in 2023.
  • A 4-year view of FCF Margin shows it stood at 27619.0% in 2022, then surged by 96bps to 1205.97% in 2023, then skyrocketed by 94bps to 74.99% in 2024, then tumbled by -376bps to 357.18% in 2025.
  • Per Business Quant, the three most recent readings for ATRA's FCF Margin are 357.18% (Q4 2025), 283.43% (Q3 2025), and 41.64% (Q2 2025).